GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Deferred Policy Acquisition Costs

Biogen (BUE:BIIB) Deferred Policy Acquisition Costs


View and export this data going back to 2019. Start your Free Trial

What is Biogen Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Biogen (BUE:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.